FY2025 Earnings Forecast for HALO Issued By Leerink Partnrs

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will earn $4.96 per share for the year, down from their previous forecast of $5.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.57 EPS, FY2026 earnings at $7.05 EPS, FY2027 earnings at $8.77 EPS and FY2028 earnings at $9.16 EPS.

HALO has been the topic of several other research reports. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Trading Down 0.6 %

Shares of NASDAQ HALO opened at $53.83 on Wednesday. The firm has a 50 day moving average price of $49.95 and a two-hundred day moving average price of $54.06. The stock has a market cap of $6.85 billion, a P/E ratio of 17.82, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC bought a new position in Halozyme Therapeutics in the 3rd quarter valued at about $1,886,000. Segall Bryant & Hamill LLC grew its holdings in Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after buying an additional 49,856 shares in the last quarter. Retirement Systems of Alabama grew its holdings in Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after buying an additional 74,173 shares in the last quarter. Creative Planning lifted its stake in Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 11,249 shares in the last quarter. Finally, South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $9,812,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.